Onychodystrophy DNA Test
Target Treatment with Bako’s Onychodystrophy DNA Test
We Know Nail Infections are Difficult to Diagnose & Expensive to Treat
TARGETED TECHNOLOGY. Knowing the genus/species of the causative agent with 99.9% analytical specificity allows for targeted therapy.1
ACCURATE. Correlates highly with gold standard histology with 86% sensitivity, while providing identification of genus/species.1
TIMELY. Rapid results in 24-48 hours mean the right treatment, right away.
COST EFFECTIVE. Quick identification of genus/species supports informed treatment decisions that can more quickly lead to effective outcomes.2.
REQUIRED. Many payors require precise identification of fungal species for preauthorization of anti-fungal Rx.
COVERED. Bako’s onychodystrophy DNA test is covered by Medicare and most insurance plans.
Relevant, Cost-Effective and Tiered DNA Testing Workflow
We are the only laboratory that optimizes cost using a proprietary reflex testing workflow that identifies the relevant agents of disease. Not all genus/species are treated the same.
Let Bako’s onychodystrophy DNA testing help you determine the safest and most effective oral and topical treatment.
click image to enlarge
Include Bako’s Onychodystrophy DNA Testing with Histology for the Highest Sensitivity and Specificity Diagnostic Testing Available
Gain all the advantages of Bako’s onychodystrophy DNA test, plus the added benefit of testing the sample for trauma, neoplastic processes and non-infectious nail diseases, when you include DNA testing with histopathology.
click image to enlarge
Bako’s Onychomycosis DNA Testing Intelligence Report
Bako’s onychodystrophy DNA testing report identifies genus and species while providing medically relevant information to help optimize care
click image to enlarge
click image to enlarge
National Health Plans’ Requirements
Antifungal pharmacy programs require positive lab report at the species level and reference DNA availability
Additional Pathology Services
Histopathologic, histochemical, and/or immunophenotypic examination of skin, soft tissue, bone, and cytology obtained though biopsy, excision amputation
Conventional growth-based microbiology testing for the presence of microorganisms in a sample
Qualification and quantification of small fiber peripheral neuropathy
Utilizes immunohistochemistry and morphometric analysis
REFERENCES
- Bako Diagnostics’ internal data
- Based on FDA product labeling indications and usage
- Chandran, N. S., J. Y. Pan, Z. A. Pramono, H. H. Tan and C. S. Seow (2013). “Complementary role of a polymerase chain reaction test in the diagnosis of onychomycosis.” Australas J Dermatol 54(2): 105-108.
- Ghannoum, M A, et al. “A Large-Scale North American Study of Fungal Isolates from Nails: the Frequency of Onychomycosis, Fungal Distribution, and Antifungal Susceptibility Patterns.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Oct. 2000